Esperion dives, despite positive Ph III results for bempedoic acid

8 March 2018
esperion-big

Despite releasing encouraging new data on its cholesterol lowerer, US lipid management firm Esperion Therapeutics (Nasdaq: ESPR) saw its shares plunged as much as 10.2% before paring some of those losses and finishing at $76.29, down 2.1% yesterday.

Esperion announced positive top-line results from the first pivotal, Phase III study (Study 4 or 1002-048) of bempedoic acid 180 mg evaluating the low density lipoprotein cholesterol (LDL-C) lowering efficacy and safety and tolerability of bempedoic acid versus placebo in patients with atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD with hypercholesterolemia inadequately treated with background ezetimibe 10 mg and up to the lowest daily starting dose of a statin.

The 12-week study met its primary endpoint with LDL-C lowering totaling 28% (p<0.001). The LDL-C lowering for the bempedoic acid group was 23% from baseline, as compared to an LDL-C increase of 5% for the placebo group. Patients treated with bempedoic acid also achieved a significantly greater reduction of 33% in high-sensitivity C-reactive protein (hsCRP), an important marker of the underlying inflammation associated with cardiovascular disease, compared to the placebo group which had an increase of two percent (p<0.001).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical